FDA okays first cardiac myosin inhibitor

FDA okays first cardiac myosin inhibitor

Approval was based on the phase 3 Explorer-HCM trial in 251 patients with New York Heart Association class II–III obstructive HCM, all of whom had left ventricular ejection fraction (LVEF)>55% or higher. Because the drug, an allosteric small moleule, depresses cardiac contractility by inhibiting cardiac-specific myosin, adverse reactions were a concern. But none of the subjects experienced left ventricular ejection fraction ≤30% nor congestive heart failure, syncope or sudden cardiac death in the Camzyos group. Two patients who transiently experienced LVEF ≤50% interrupted treatment and resumed it on a lower dose.

This is a preview of subscription content

Access options

Subscribe to Journal

Get full journal access for 1 year

99,00 €

only 8,25 € per issue

Tax calculation will be finalised during checkout.

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

About this article

Cite this article

FDA okays first cardiac myosin inhibitor.
Nat Biotechnol 40, 809 (2022). https://doi.org/10.1038/s41587-022-01374-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-022-01374-3

Read More

Author: admin